297 related articles for article (PubMed ID: 36831300)
21. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
22. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
Front Immunol; 2021; 12():695051. PubMed ID: 34413848
[TBL] [Abstract][Full Text] [Related]
23. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
[TBL] [Abstract][Full Text] [Related]
24. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
25. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F; Cooper B; Caimi P; Zamborsky K; Reese-Koc J; Hillian A; Hernandez-Collazo Y; Lee G; Boughan K; Tomlinson B; Gallogly M; Metheny L; Bajor D; Selfridge J; Saltzman J; Lazarus H; de Lima M; Wald D
Transplant Cell Ther; 2022 May; 28(5):250.e1-250.e8. PubMed ID: 35172204
[TBL] [Abstract][Full Text] [Related]
26. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.
Kordelas L; Steckel NK; Horn PA; Beelen DW; Rebmann V
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801784
[TBL] [Abstract][Full Text] [Related]
27. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
28. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
29. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
Front Immunol; 2019; 10():1218. PubMed ID: 31214182
[TBL] [Abstract][Full Text] [Related]
30. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
31. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
32. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
[TBL] [Abstract][Full Text] [Related]
33. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
34. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
35. NK cell defects: implication in acute myeloid leukemia.
D'Silva SZ; Singh M; Pinto AS
Front Immunol; 2023; 14():1112059. PubMed ID: 37228595
[TBL] [Abstract][Full Text] [Related]
36. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
37. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
[TBL] [Abstract][Full Text] [Related]
38. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
39. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient.
Beck C; Humpe A; Harder S; Schmid M; Horst HA
Ann Hematol; 2005 Sep; 84(9):616-8. PubMed ID: 15782344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
